After Pfizer & SII, Bharat Biotech Too Seeks Emergency Use Approval For Covaxin

Hyderabad: Pfizer and the Serum Institute of India (SII) had already sought emergency use approval for their COVID-19 vaccines from the Drug Controller General of India (DCGI).

Now, Hyderabad-based Bharat Biotech followed suit in urging the DCGI for the approval for its indigenously made COVID vaccine Covaxin, reported India Today.

Bharat Biotech is indigenously developing Covaxin in association with the Indian Council of Medical Research (ICMR).

The Phase 3 trials of the respective vaccine candidates of both SII and Bharat Biotech are currently being conducted in India.